UK markets open in 58 minutes
NIKKEI 225
37,936.40 +307.92 (+0.82%) HANG SENG
17,702.12 +417.58 (+2.42%) CRUDE OIL
84.04 +0.47 (+0.56%) GOLD FUTURES
2,350.10 +7.60 (+0.32%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,618.12 +263.68 (+0.51%)
BioInvent International AB (publ) (0H22.L)
LSE - LSE Delayed price. Currency in SEK
Add to watchlist
At close: 05:13PM BST
| Previous close | 44.54 |
| Open | 44.54 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 44.54 - 44.54 |
| 52-week range | 14.60 - 44.54 |
| Volume | |
| Avg. volume | 1,194 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.55 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients
© 2024 Yahoo. All rights reserved.